ASTELLAS-015K-CL-PS01

Study Sponsor: Astellas

Study Title

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis

Medicine or Vaccine (generic name)

peficitinib hydrobromide

Sponsor Identification Number

015K-CL-PS01

Trial Registry Identification Number(#'s)

NCT01096862

Medical Condition

Psoriasis

Phase

Phase 2

Link to Astellas Study Register

https://www.clinicaltrials.astellas.com/study/015K-CL-PS01

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT01096862

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

March 2020